Nervous system dysregulation impacts health, linking stress responses to mental and physical conditions. Understand its ...
The development of drugs to treat major diseases of the central nervous system relies in part on the development of novel strategies to cross the blood brain barrier. Michel Khrestchatisky and ...
Clinical Trials Arena on MSN6d
Cassava ends simufilam Alzheimer’s programme after second Phase III failureWhile Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in ...
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...
We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback